Perioperative Durvalumab Regimen Improves EFS and OS in Muscle-Invasive Bladder Cancer
Clinical Trials
Misinformation Drives Over 16 Million Americans Toward High Skin Cancer Risk
SUNRISE-II Trial Begins Evaluating Ultrasound-Guided HIFU Ablation for Pancreatic Cancer
OPTIMAL Data Support TLX597-Tx as a Next-Gen Radioligand Therapy in Prostate Cancer
Phase 3 MagnetisMM-5 Trial Supports Earlier Use of Elranatamab in Relapsed Myeloma
Dual Pathway Blockade Achieves 40% Response in Clear Cell Gynaecological Cancer
World’s First Nectin-4-Targeting ADC Enters Phase III Trial in Triple-Negative Breast Cancer
AI Predicts Chemotherapy Benefit in Breast Cancer Using Routine Pathology Slides
Amivantamab Plus Chemotherapy Shows Promising Responses in Colorectal Cancer
TRBC2-Specific ADC Shows Robust Efficacy in T-Cell Lymphomas and Leukemias
Platinum-Free PADCEV Plus Pembrolizumab Improves Survival in MI Bladder Cancer
Less Toxic, More Effective: RW Evidence Supports Reduced Immunotherapy Dose in Melanoma
Preoperative Radiation May Improve Immune Response in HR+ HER2- Breast Cancer
Giredestrant Cuts Risk of Invasive Recurrence by 30% in Early ER+ Breast Cancer
Tucatinib Combination Cuts Progression Risk by 36% in HER2+ Metastatic Breast Cancer
Teclistamab plus Daratumumab Achieves an 83% Risk Reduction in R/R Multiple Myeloma
Ribociclib Maintains Long-Term Disease Control in HR+ HER2 Metastatic Breast Cancer
Enozertinib Shows Strong Systemic and CNS Activity in EGFR Exon 20+ NSC Lung Cancer
NEJM Study Confirms Low-Dose Aspirin Halves Recurrence in Colorectal Cancer
Breaking the Molecular Link Between Alcohol and Pancreatic Cancer by Targeting CREB
Promising Results: Jaypirca Outperforms Imbruvica in Landmark Phase 3 CLL/SLL Trial
START and OneOncology Partnership Expands Clinical Trials from Academia to Community
DNA-Based Immunotherapy IMNN-001 Shows Survival Gains in Advanced Ovarian Cancer
START Doses First Patient in Trial of mRNA-4106, a Pan-Tumor Therapy for Solid Tumors
10-Year Results Confirm Pertuzumab Combo Extends Survival in HER2+ Breast Cancer
EpCAM-Targeting ADC CX-2051 Shows Promising Efficacy in Advanced Colorectal Cancer
Leucid Bio Doses First Patient in Trial of LEU011, a CAR-T Therapy for Solid Tumors
Durvalumab Plus BCG Boosts Outcomes in Early-Stage Bladder Cancer
Enhertu Outperforms Chemotherapy in Early-Stage HER2+ Breast Cancer
Elraglusib Shows Survival Benefit in First-Line Metastatic Pancreatic Cancer Trial
Subscribe for the latest news and events
Most Popular
Improving Everolimus Safety in Oncology: Missed Opportunities in Risk Minimization
FDA Approves Wegovy to Reduce Risk of Heart Problems in Obese Adults
Targeting the ‘Don’t Eat Me’ Signal: The Future of Macrophage Checkpoint Inhibitors
A New Era in Liver Disease: FDA Approves First Medication 'Rezdiffra' for NASH
Zongertinib Gains FDA Accelerated Approval for HER2+ NSCLC with 75% ORR
Exploring the Transformative Power of AI in Drug Discovery: A report by S&P Global
FDA Grants Accelerated Approval to Semaglutide for MASH with Liver Fibrosis
NETTER-2 Trial: Lutathera Cuts Risk of Death by 72% in Neuroendocrine Tumor Treatment
Bayer Poised for Landmark Year with Blockbuster Treatment Advances Across Key Diseases
Transformative One-Time Gene Therapy: FDA Approves Pfizer's BEQVEZ, for Hemophilia B
FDA Approves Groundbreaking CAR T Cell Therapy, Abecma, for Multiple Myeloma
New Horizon in Food Allergy Treatment: FDA Approves Xolair for All Ages
FDA Approves Carvykti as Targeted CAR-T Cell Therapy for Multiple Myeloma
